癌症恶病质发病机制与治疗研究进展  

Progress in Cancer Cachexia Pathogenesis and Treatment

作　　者：温宏升[1] 阎飞[1] 秦贤举[1] 

机构地区：[1]上海市第八人民医院肿瘤科,上海200233

出　　处：《医学综述》2016年第4期722-725,共4页Medical Recapitulate

摘　　要：癌症恶病质(CC)是晚期恶性肿瘤常见并发症。近十年,尽管CC发生机制的研究取得了一些新进展,但其治疗尚缺乏理想的方法。CC病理生理机制复杂,涉及系统性炎症反应、脂肪代谢和蛋白质代谢等多种因素。CC的成功治疗也有赖于多途径干预,包括营养支持和多种药物联合运用。目前临床上用于治疗CC的药物有沙利度胺、非甾体消炎药类、孕酮类等;另外,一些根据其发病机制设计的新药尚处于临床研究阶段(如ALD518、OHR/AVR118等)。Cancer cachexia is a common complication of advanced cancer. Over the last decade,we have gained new insight into the pathophysiology of cancer cachexia. Unfortunately, its treatment remains a challenge. Cancer cachexia is a multifactorial syndrome, which is mainly related to systemic inflammatory reaction, lipid metabolism and protein metabolism, etc. The successful management of cancer cachexia will likely require the multimodal approaches that include nutritional support and combination of pharmaceutical interventions. The current drugs in clinic for treatment of cancer cachexia include thalidomide, nonsteroid antiinflammatory drugs, progesterone drugs, etc. In addition, some new drugs designed according to the cancer cachexia pathogenesis are still in the clinical research stage, such as ALDS18, OHR/AVR118, etc.

关 键 词：癌症恶病质 发病机制 药物治疗 

分 类 号：R730.6[医药卫生—肿瘤]